丹参多酚酸盐对不稳定型心绞痛患者PCI围术期的疗效分析

对照组，各48例。两组均常规应用抗心肌缺血药物、β-受体阻滞剂、阿司匹林、氯吡格雷、他汀类药物、血管紧张素转换酶抑制剂（angiotensin converting enzyme inhibitors，ACEI）/血管紧张素Ⅱ受体拮抗剂（angiotensin receptor blocker，ARB）、低分子肝素，治疗组于PCI术前连用丹参多酚酸盐（200 mg/d）治疗3 d，术前术后共应用8 d。观察两组患者的临床疗效及围手术期低密度脂蛋白胆固醇LDL-C、hs-CRP、hs-cTnI、CK-MB、Hcy、D-二聚体、血黏度的变化，并随访3个月观察主要心脑血管事件以及药物不良反应。结果 治疗组较对照组总有效率升高（95.83% vs 81.25%）（P<0.05）。与对照组治疗后相比，治疗组治疗后hs-CRP、CK-MB、Hcy、D-二聚体、血黏度水平均较低，差异有统计学意义（P<0.05）。随访3个月主要心脑血管事件发生率分别为4.17%与18.75%（P<0.05）。 结论 丹参多酚酸盐注射液可改善不稳定型心绞痛患者临床疗效，不增加出血风险，具有良好的安全性和可行性。

[关键词] 丹参多酚酸盐；不稳定性心绞痛；PCI围术期；心肌保护

[中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701（2016）21-0099-05

[Abstract] Objective To review the perioperative effect of salvianolate injection in patients with unstable angina pectoris（UAP） during percutaneous coronary intervention（PCI） period. Methods From Jan 2015 to February 2016，a total of ninety-six patients were included in this study. Those patients with UA were randomly divided into the therapy group（salvianolate set）and the control group with forty-eight cases in each. Two groups were given routinely drugs such as anti-ischemic drug therapy， beta-blocker， aspirin， clopidogrel， statins， ACEI/ARB and low molecular heparin，while the therapy group was administered with salvianolate（200 mg/d） three days additionally. Therapy group was treated for 8 days in whole perioperative. The clinical efficacy， the levels and the changes of LDL-C，hs-CRP，hs-cTnI，CK-MB，Hcy，D-dimer and blood viscosity during perioperative were observed between the two groups. During the 3 months follow-up， the occurrence of adverse major adverse cardiac or cerebral events and drug adverse reactions were compared between two groups. Results After the treatment，the total effective rates were 95.83% in the therapy group and 81.25% in the control group， with a significant difference（P<0.05）. Compared with the control group the level of hs-CRP， hs-cTnI， CK-MB， Hcy， D-dimer and blood viscosity decreased obviously in the therapy group， with a significant difference（P<0.05）. After three months of follow-up，the total incidence rates of cardiac or cerebral events were 4.17% in the therapy group and 18.75% in the control group， with a significant difference（P<0.05）. Conclusion Peri-PCI salvianolate use is safe and effective related with low bleeding risk in patients with UA，and it can improve the clinical therapeutic effect.